The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease
Open accessAbstract
The apolipoprotein E (APOE) ε2 allele has been associated with both Parkinson's disease (PD) and lower low‐density lipoprotein cholesterol (LDL‐C). We tested the hypothesis that lower LDL‐C may be associated with PD. This case–control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age, gender, smoking status, and use of cholesterol‐lowering agents. Lower LDL‐C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL‐C (≥138 mg/dL), the OR was 2.2 (95% CI = 0.9–5.1) for participants with LDL‐C of 115 to 137, 3.5 (95% CI = 1.6–8.1) for LDL‐C of 93 to 114, and 2.6 (95% CI = 1.1–5.9) for LDL‐C of ≤ 92. Interestingly, use of either cholesterol‐lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL‐C may be associated with higher occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation. © 2007 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data.
Craig, W. Y., Palomaki, G. E., & Haddow, J. E. (1989) · BMJ · doi:10.1136/bmj.298.6676.784 · Cited by 863
Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study
Wilson, P. W. F. (1994) · JAMA · doi:10.1001/jama.1994.03520210050031 · Cited by 468
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397
Risk tables for parkinsonism and Parkinson’s disease
Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00425-5 · Cited by 377
Cited by
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Hippisley-Cox, J., & Coupland, C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 512
Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases
Vance, J. E. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010124 · Cited by 342
Yeger-Lotem, E., Riva, L., Su, L. J., Gitler, A. D., Cashikar, A. G., King, O. D., Auluck, P. K., Geddie, M. L., Valastyan, J. S., Karger, D. R., et al. (2009) · Nature Genetics · doi:10.1038/ng.337 · Cited by 286
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
Cholesterol metabolism in the brain and its association with Parkinson’s disease.
Jin, U., Park, S. J., & Park, S. M. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.554 · Cited by 169
Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases
Wang, Q., Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., & Yenari, M. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2010.04.006 · Cited by 130
Huang, X., Abbott, R. D., Petrovitch, H., Mailman, R. B., & Ross, G. W. (2008) · Movement Disorders · doi:10.1002/mds.22013 · Cited by 124
Self-citationMetabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., et al. (2020) · Aging · doi:10.18632/aging.103992 · Cited by 50
Novel subcellular localization for α-synuclein: possible functional consequences
Guardia-Laguarta, C., Area-Gomez, E., Schon, E. A., & Przedborski, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00017 · Cited by 44
Yazdani, S., Mariosa, D., Hammar, N., Andersson, J., Ingre, C., Walldius, G., & Fang, F. (2019) · Annals of Neurology · doi:10.1002/ana.25614 · Cited by 42
Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
Godoy-Corchuelo, J. M., Fernández-Beltrán, L. C., Ali, Z., Gil-Moreno, M. J., López-Carbonero, J. I., Guerrero-Sola, A., Larrad-Sainz, A., Matias-Guiu, J., Matias-Guiu, J. A., Cunningham, T. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10051105 · Cited by 35
APOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease
Singh, N. K., Banerjee, B. D., Bala, K., Mitrabasu, Dung Dung, A. A., & Chhillar, N. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1651-6 · Cited by 31
Metadata
- Authors
- Huang, X., Chen, H., Miller, W. C., Mailman, R. B., Woodard, J. L., Chen, P. C., Xiang, D., Murrow, R. W., Wang, Y., & Poole, C.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2006-12-18
- Volume
- 22
- Issue
- 3
- Pages
- 377-381
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2012650310
- Cited by
- 189
- References
- 6
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.